Semaglutide 3 mg Tablets

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and increases satiety. The 3 mg strength supports higher-dose chronic weight management in patients requiring greater metabolic support.

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity such as hypertension, dyslipidaemia, or type 2 diabetes.

The recommended maintenance dose is 3 mg taken orally once daily. Therapy is initiated at a lower dose and escalated in stepwise increments over 16 weeks to the 3 mg maintenance dose to minimise gastrointestinal effects.

Swallow the tablet whole with water. Take once daily at the same time each day, with or without food. Do not crush or chew. If a dose is missed for more than 5 days, resume on the scheduled day.

Adults with obesity or overweight with weight-related comorbidity. Not for use in type 1 diabetes or diabetic ketoacidosis. Avoid in pregnancy and breastfeeding. Use cautiously in patients with retinopathy, pancreatitis history, or severe renal impairment.

Common: nausea, vomiting, diarrhoea, constipation, dyspepsia, fatigue, dizziness. Less common: pancreatitis, gallstones, hypoglycaemia (when used with insulin or sulfonylureas).

History of MTC or MEN 2; hypersensitivity to semaglutide; pregnancy. Not for co-administration with other semaglutide-containing products or other GLP-1 receptor agonists.

Store below 25°C in original packaging. Protect from moisture and light. Keep out of reach of children.